

Estimate changes	↔
TP change	↔
Rating change	↔

Bloomberg	DABUR IN
Equity Shares (m)	1774
M.Cap.(INRb)/(USDb)	833.6 / 8.8
52-Week Range (INR)	577 / 401
1, 6, 12 Rel. Per (%)	8/-5/-2
12M Avg Val (INR M)	1216

#### Financials & Valuations (INR b)

Y/E March	2026	2027E	2028E
Sales	131.9	143.8	154.3
Sales Gr. (%)	5.0	9.0	7.3
EBITDA	24.5	27.1	29.9
EBITDA mrg. (%)	18.6	18.9	19.4
Adj. PAT	19.4	20.9	23.1
Adj. EPS (INR)	10.9	11.8	13.0
EPS Gr. (%)	7.6	8.0	10.4
BV/Sh.(INR)	64.4	65.8	66.9

#### Ratios

RoE (%)	17.5	18.1	19.7
RoCE (%)	16.1	16.3	17.6
Payout (%)	86.9	93.1	95.9

#### Valuation

P/E (x)	43.0	39.8	36.0
P/BV (x)	7.3	7.1	7.0
EV/EBITDA (x)	30.5	27.4	24.7
Div. Yield (%)	2.0	2.3	2.7

#### Shareholding pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	66.3	66.2	66.3
DII	18.6	18.4	15.7
FII	10.0	10.1	12.7
Others	5.2	5.3	5.4

FII Includes depository receipts

**CMP: INR470**

**TP: INR475 (+1%)**

**Neutral**

## Steady show; HPC outperformance sustains

- Dabur's (DABUR) consolidated revenue grew ~7% YoY (flat base), with India business revenue up 10% YoY. Demand recovery was noted in steady double-digit growth in HPC in 2HFY26. India volume grew 6% (est: 4%, 3% in 3Q). Demand condition in India remained steady; however, unseasonal rains in March impacted its summer portfolio (glucose, nectars etc.). Rural markets continued to outpace urban consumption by ~350bp. Going ahead, management expects 4Q growth momentum to continue in HPC and healthcare (excl. glucose).
- Home & personal care continued to drive growth, with revenue up 17%, backed by hair care and home care. The healthcare portfolio posted ~4% growth. F&B grew 3% YoY. Management has revised its India business revenue guidance from high single digits to low double digits, anticipating growth from both volume and pricing (largely equal split) for FY27.
- GM expanded 160bp YoY to 48.3% (est: 47.1%), while EBITDA margin remained flat YoY at 15.2% (in line). Amid geopolitical tensions, Dabur is seeing cost inflation of ~10%, and to offset this, the company has taken ~4% price hike. Management remains open to further pricing action depending on RM prices. Dabur aspires to improve operating margins by mitigating inflation through price increases, premiumization, and cost-saving initiatives. We build in a modest margin expansion and expect EBITDA margin to be ~19% for FY27/FY28E.
- Dabur expects double-digit growth across its business verticals in FY27, along with margin improvement. Management expects a healthy mix of volume and value going ahead. Dabur's performance is quite sensitive to macro recovery, particularly rural demand. General macro inflation and monsoon will be key monitorable for its FY27 performance. **We reiterate our Neutral rating on the stock with a TP of INR475 (based on 35x Mar'28E EPS).**

## In-line EBITDA; HPC continues to lead growth

- **Improved India growth; positive commentary for FY27:** 4Q consolidated sales grew 7% (est:3.5%) to INR30.4b (est. INR29.3b). India business revenue grew 10% YoY. India business volume grew 6%. (est. 4%).
- **HPC business up ~17% YoY on negative 3% base:** HPC continued its healthy performance trajectory in 4Q, aided by broad-based performance across categories and a favorable base (-3% in 4QFY25). Hair Care portfolio grew by ~27% (-5% in base) during the quarter, led by 28% growth in Hair Oils business. Home care grew in mid-twenties, backed by strong growth in Odonil. The toothpaste category was up ~7% YoY, leading to oral care growth of mid-single digit. Skin & Salon business grew by over 12%.

**Naveen Trivedi – Research Analyst** (Naveen.Trivedi@motilaloswal.com)

**Research Analyst: Amey Tiwari** (Amey.Tiwari@motilaloswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **Healthcare portfolio up ~4% YoY:** Health supplements grew 2.2% YoY (3.6% - excl. the impact of discontinued brands – Baby Super Pants and Vedic Tea). Dabur honey grew in twenties, while Dabur Glucose sales were impacted by unseasonal rains in Mar'26. This led to health supplements revenue declining in mid-single digits. Digestives business grew 15% YoY and OTC & Ethicals grew in double digits.
- **Foods and beverages grew ~3% YoY:** The Culinary portfolio accelerated its growth momentum during the quarter and reported growth in twenties with broad-based growth across brands. Beverage portfolio witnessed a sequential recovery in 4Q. In beverages, Real active and coconut water are doing exceedingly well, while nectar was impacted by rains. Premium beverage portfolio continued to outperform the category. Badshah business performed well, with domestic growth in double digits (+12%).
- Despite facing headwinds in the Middle East, **international business grew by 2.5% (INR terms)** during the quarter, led by Sub-Saharan Africa (20%), UK & EU {10%}; Namaste US (6.2%) and Bangladesh (22%).
- **Flat EBITDA margin:** Gross margin expanded 160bp YoY (flat QoQ) to 48.3% (est. 47.1%). Employee expenses rose 15% (-7% in base), ad spends grew 22% and other expenses rose 7% YoY. EBITDA margin expanded 10bp YoY to 15% (est. 15.6%).
- **High other income leads to profitability beat:** EBITDA grew 8% (on 8% decline in base) to INR4.6b (est. INR4.6b) and APAT grew by 15% YoY (on 8% decline in base) to INR3.8b (est. INR3.5b). Beat on APAT was on account of higher-than-expected other income.
- In FY26, net sales, EBITDA, and APAT grew 5%, 6% and 8%, respectively.

### Highlights from the management commentary

- Demand condition in India remained steady, though unseasonal rains in Mar'26 impacted summer portfolio business. Dabur's India business grew 9.5% YoY, while the FMCG sector saw 9.2% growth as per Dabur.
- Dabur is seeing inflation of ~10%, and to offset this, Dabur has taken ~4% price hike at company level. Packaging material constitutes one-third of the raw material basket, and its costs have increased due to rising crude prices.
- Management revised India business revenue guidance from high single-digits to low double-digits, anticipating growth from both volume and pricing (largely equal split) for FY27.

### Valuation and view

- We largely maintain our EPS estimates for FY27E and FY28E.
- The company has been witnessing muted sales growth over the past two years. After delivering 1.3% growth in FY25, revenue growth improved modestly to 5% in FY26. Management has revised India business revenue guidance from high single-digit to low double-digit, anticipating growth from both volume and pricing (largely equal split) for FY27.
- While we remain positive on India consumption, DABUR's historical weak execution remains concerning to us. General macro inflation and monsoon will be key monitorable for its FY27 performance. **We reiterate our Neutral rating on the stock with a TP of INR475 (based on 35x Mar'28E EPS).**

**Quarterly Performance (Consolidated)**

(InR m)

Y/E March	FY25				FY26				FY25	FY26	FY26E	Var. (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
<b>Domestic FMCG vol. growth (%)</b>	<b>5.2</b>	<b>-7.0</b>	<b>1.2</b>	<b>-5.0</b>	<b>-1.0</b>	<b>2.0</b>	<b>3.0</b>	<b>6.0</b>	<b>-1.4</b>	<b>2.5</b>	<b>4.0</b>	
<b>Net sales</b>	<b>33,491</b>	<b>30,286</b>	<b>33,553</b>	<b>28,301</b>	<b>34,046</b>	<b>31,913</b>	<b>35,587</b>	<b>30,380</b>	<b>125,631</b>	<b>131,926</b>	<b>29,283</b>	3.7%
YoY change (%)	7.0	-5.5	3.1	0.6	1.7	5.4	6.1	7.3	1.3	5.0	3.5	
<b>Gross profit</b>	<b>16,005</b>	<b>14,943</b>	<b>16,124</b>	<b>13,211</b>	<b>16,013</b>	<b>15,778</b>	<b>17,218</b>	<b>14,679</b>	<b>60,282</b>	<b>63,688</b>	<b>13,789</b>	6.5%
Margin (%)	47.8	49.3	48.1	46.7	47.0	49.4	48.4	48.3	48.0	48.3	47.1	
<b>EBITDA</b>	<b>6,550</b>	<b>5,526</b>	<b>6,819</b>	<b>4,269</b>	<b>6,678</b>	<b>5,881</b>	<b>7,341</b>	<b>4,618</b>	<b>23,163</b>	<b>24,518</b>	<b>4,565</b>	1.2%
Margins (%)	19.6	18.2	20.3	15.1	19.6	18.4	20.6	15.2	18.4	18.6	15.6	
YoY growth (%)	8.3	-16.4	2.1	-8.6	2.0	6.4	7.7	8.2	-3.5	5.8	6.9	
Depreciation	1,091	1,110	1,086	1,169	1,141	1,154	1,172	1,222	4,456	4,689	1,194	
Interest	327	474	442	393	346	397	311	400	1,635	1,454	421	
Other income	1,294	1,515	1,280	1,412	1,440	1,401	1,406	1,750	5,501	5,998	1,456	
<b>PBT</b>	<b>6,427</b>	<b>5,457</b>	<b>6,571</b>	<b>4,119</b>	<b>6,630</b>	<b>5,731</b>	<b>7,265</b>	<b>4,747</b>	<b>22,573</b>	<b>24,373</b>	<b>4,406</b>	7.7%
Tax	1,481	1,284	1,418	992	1,543	1,282	1,575	1,117	5,175	5,517	1,126	
Rate (%)	23.0	23.5	21.6	24.1	23.3	22.4	21.7	23.5	22.9	22.6	25.6	
<b>Adjusted PAT</b>	<b>5,084</b>	<b>4,333</b>	<b>5,306</b>	<b>3,284</b>	<b>5,222</b>	<b>4,608</b>	<b>5,795</b>	<b>3,769</b>	<b>18,006</b>	<b>19,393</b>	<b>3,500</b>	7.7%
YoY change (%)	7.7	-17.2	1.6	-8.2	2.7	6.4	9.2	14.8	-4.0	7.7	6.6	

E: MOFSL Estimates

**Exhibit 1: Category-wise performance**

Business Segment	Category	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26
Healthcare	Health Supplements	7.8	-11.2	-3.4	0.5	3	5	3	(5)
	Digestives	10.7	-7.7	3.9	-2.1	7.7	2	5	15
	OTC & Ethical	3.7	-14	0.4	-8.4	2	-5	5	7
Home and Personal Care	Oral Care	11.4	-8.7	9.1	-5.2	5	14.3	10	5
	Hair care	3.3	-10.2	2.7	-4.6	2	5	10	27
	Home care	8	-4.9	5	0.9	10.1	5	2	24
Foods & Beverages (incl Badshah)	Skin & Salon	6.1	-14	5.6	8	9.2	8	5	12
		26.0	19.5	17.2	26.1	22.9	19.1	16.4	25

Sources: Company reports, MOFSL


**Highlights from the management commentary**
**Demand and Environment**

- Heightened geopolitical tensions in the Middle East drove inflation, elevated freight costs, and impacted consumer demand in select markets.
- Demand condition in India remained steady, though unseasonal rains in Mar'26 impacted summer portfolio business.
- Dabur's India business grew 9.5% YoY, while the FMCG sector grew 9.2%, as per Dabur.
- Rural markets continued to outpace urban consumption, with rural demand growing ahead of urban India by 350bp.
- In 4Q, Dabur witnessed double-digit growth in Amla franchise, Vatika Shampoo, Real Activ, Dabur Honey, Dabur Honitus, Hajmola, Dabur Health Juices and Dabur Meswak.
- **Dabur is seeing inflation of ~10% and to offset this, Dabur has taken ~4% price hike at company level.**
- To mitigate inflationary pressures, the company is implementing price increases and reducing grammage in INR10/INR20 packs.
- Packaging material constitutes one-third of the raw material basket, and its costs have increased due to rising crude prices.

- Beverage portfolio witnessed a sequential recovery in 4Q. In beverages, Real active and coconut water are doing exceedingly well, while nectar was impacted by rains. Premium beverage portfolio continued to outperform the category, delivering a robust growth of 26% in real active juices and coconut water, doubling YoY.
- Dabur's GT business has grown by ~5%.
- Within Urban India, e-commerce and Modern Trade have been driving demand, growing by 49% and 19%, respectively.
- Quick Commerce is driving the online business, up 54%. This channel was a major contributor to Dabur's Foods business, which grew by 30% in 4Q.
- Despite facing headwinds in the Middle East, international business grew by 2.5% during the quarter, led by Sub-Saharan Africa (20%), UK & EU (10%); Namaste US (6.2%) and Bangladesh (22%).
- Dabur has launched 'SIENS', Dabur's first online only Direct-to-Consumer nutraceutical brand, which is showing great consumer traction.

#### Guidance

- In 1Q, growth is expected to sustain. Management expects growth momentum to continue in HPC and healthcare (ex-glucose).
- **Management revised India business revenue guidance from high single-digits to low double-digits, anticipating growth from both volume and pricing (largely equal split) for FY27.**
- Dabur expects sequential growth acceleration in India business, driven by stable consumption, GTM transformation, premiumization, and brand investments.
- In FY27, the company expects HPC to grow in the double-digit to high-teen range, while oral care and home will continue the double-digit trend. F&B will also post double-digit growth, depending on weather conditions.
- **Dabur expects further price hikes at company level, depending on RM prices.**
- **Dabur aspires to improve operating margins by mitigating inflation through price increases, premiumization, and saving initiatives.**

#### Segmental performance

##### HPC

The HPC portfolio delivered 16.8% YoY growth, driven by broad-based performance across categories.

##### Oral Care

- The toothpaste category was up by over 7% YoY.
- Toothpastes recorded high-single growth, led by steady momentum in Dabur Red Toothpaste. Dabur Meswak and Dabur Herbal continue to outpace category growth in toothpastes with market share gains.

##### Skin Care

- Dabur's Skin & Salon business grew by over 12%.
- Dabur Gulabari franchise ended 4Q on strong footing with double-digit growth.
- During the quarter, Facial kit portfolio continued its robust growth momentum.

### Home Care

- Odonil grew in mid-twenties, supported by strong growth momentum in aerosols and new premium fragrances in blocks.
- Portfolio continued to strengthen its position and gained market share.
- Sanifresh and Odomos both performed well and grew in strong double digits.

### Hair Care

- Dabur's Hair Care portfolio grew by ~27% during the quarter, led by the Hair Oils business, which reported 28% growth.
- In Hair oils, there was price growth of 9% and volume growth of ~14%. The coconut hair oil portfolio grew by 48%.
- Hair oil growth was led by Amla franchise, Dabur Almond and Anmol coconut.
- Hair oil portfolio registered market share gains.
- Shampoo category registered growth in early twenties and market share gains.

### Healthcare

Healthcare grew 3.2% YoY, excluding Baby Super Pants and Vedic Tea; reported growth stood at 2.2%.

### Health Supplements

- Health supplements witnessed mid-single digit decline.
- Dabur Honey reported double-digit growth in twenties.
- Dabur Glucose sales were impacted by unseasonal rains in Mar'26, but market share gains continued.

### Digestives

- The business grew 15% YoY.
- Hajmola franchise grew in double digits and gained market share.
- Pudín Hara grew in mid-single digits, with fizz variants continuing to perform well.

### OTC & Ethicals


- Dabur Lal Tail grew in double digits during the quarter on the back of focused interventions and media spending.
- Dabur Honitus continued its strong double-digit growth, aided by the differentiated positioning around quicker and faster relief from cough with giving drowsy effect.
- Health juices continued its growth momentum and registered double-digit growth.

### Food & beverages

- Culinary portfolio accelerated its growth momentum during the quarter and reported growth in twenties with broad-based growth across brands.
- Activ range, including Juices and Coconut water, maintained its strong double-digit growth momentum.
- Strong on-ground execution and consumer-led initiatives for driving engagement and offtakes led to market gain in Nectars, Real Activ juices and coconut water.
- Badshah business performed well with 12% growth.


**Key exhibits**

**Exhibit 2: Domestic FMCG business volumes rose 6% YoY in 4QFY26**




Sources: Company reports, MOFSL


**Exhibit 3: Consolidated reported net sales rose 7.3% YoY to INR30.4b**




**Exhibit 4: Con. GP margin expanded 160bp YoY to 48.3%**




**Exhibit 5: EBITDA margin expanded 10bp YoY to 15.2%**



**Exhibit 6: Ad spends grew 90bp YoY to 7.1%, and staff costs grew 70bp YoY to 11.1%, while other expenses declined 10bp YoY to 14.9%**



**Exhibit 7: Consolidated adjusted PAT rose 14.8% YoY to INR3.8b**



Sources: Company reports, MOFSL

**Valuation and view**


- We largely maintain our EPS estimates for FY27 and FY28.
- The company has been witnessing muted sales growth over the past two years. After delivering 1.3% growth in FY25, revenue growth improved modestly to 5% in FY26. Management has revised India business revenue guidance from high single-digits to low double-digits, anticipating growth from both volume and pricing (largely equal split) for FY27.
- While we remain positive on India consumption, DABUR’s historical weak execution remains concerning to us. General macro inflation and monsoon will be key monitorable for its FY27 performance. **We reiterate our Neutral rating on the stock with a TP of INR475 (based on 35x Mar’28E EPS).**

**Exhibit 8: We largely maintain our EPS estimates for FY27E and FY28E**

	New		Old		% Change	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Net Sales	143.8	154.3	141.4	151.5	1.6	1.9
EBITDA	27.1	29.9	26.9	29.1	1.0	2.8
Adjusted PAT	20.9	23.1	21.0	22.8	-0.3	1.6


Source: MOFSL

**Exhibit 9: DABUR’s P/E (x)**



Sources: Bloomberg, MOFSL

**Exhibit 10: Consumer sector’s P/E (x)**



Sources: Bloomberg, MOFSL

## Financials and valuations

### Consol. Income Statement

(InR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
<b>Net Sales</b>	<b>86,846</b>	<b>95,683</b>	<b>1,08,960</b>	<b>1,15,379</b>	<b>1,24,040</b>	<b>1,25,631</b>	<b>1,31,926</b>	<b>1,43,776</b>	<b>1,54,337</b>
Change (%)	2.0	10.2	13.9	5.9	7.5	1.3	5.0	9.0	7.3
<b>Gross Profit</b>	<b>43,434</b>	<b>47,944</b>	<b>52,563</b>	<b>52,692</b>	<b>59,571</b>	<b>60,282</b>	<b>63,688</b>	<b>69,444</b>	<b>75,317</b>
Margin (%)	50.0	50.1	48.2	45.7	48.0	48.0	48.3	48.3	48.8
Other Expenditure	25,510	27,700	29,952	30,971	35,568	37,119	39,170	42,310	45,417
<b>EBITDA</b>	<b>17,924</b>	<b>20,243</b>	<b>22,611</b>	<b>21,721</b>	<b>24,002</b>	<b>23,163</b>	<b>24,518</b>	<b>27,134</b>	<b>29,899</b>
Change (%)	3.0	12.9	11.7	-3.9	10.5	-3.5	5.8	10.7	10.2
Margin (%)	20.6	21.2	20.8	18.8	19.4	18.4	18.6	18.9	19.4
Depreciation	2,205	2,401	2,529	3,110	3,992	4,456	4,689	5,137	5,477
Int. and Fin. Charges	495	308	386	782	1,242	1,635	1,454	1,300	1,200
Other Income - Recurring	3,053	3,253	3,932	4,454	4,824	5,501	5,998	6,303	6,626
<b>Profit before Taxes</b>	<b>18,277</b>	<b>20,787</b>	<b>23,628</b>	<b>22,283</b>	<b>23,593</b>	<b>22,573</b>	<b>24,373</b>	<b>27,000</b>	<b>29,848</b>
Change (%)	1.6	13.7	13.7	-5.7	5.9	-4.3	8.0	10.8	10.5
Margin (%)	21.0	21.7	21.7	19.3	19.0	18.0	18.5	18.8	19.3
Tax	4,654	3,630	4,422	4,816	5,395	4,991	5,373	6,679	7,277
Deferred Tax	-1,857	-20	842	357	79	184	144	70	184
Tax Rate (%)	15.3	17.4	22.3	23.2	23.2	22.9	22.6	25.0	25.0
<b>Profit after Taxes</b>	<b>15,480</b>	<b>17,176</b>	<b>18,364</b>	<b>17,110</b>	<b>18,118</b>	<b>17,399</b>	<b>18,855</b>	<b>20,251</b>	<b>22,387</b>
Change (%)	1.8	11.0	6.9	-6.8	5.9	-4.0	8.4	7.4	10.5
Margin (%)	17.8	18.0	16.9	14.8	14.6	13.8	14.3	14.1	14.5
Minority Interest	25	17	31	-58	-314	-272	-263	-370	-416
<b>Adjusted PAT</b>	<b>15,454</b>	<b>17,160</b>	<b>18,333</b>	<b>17,168</b>	<b>18,757</b>	<b>18,006</b>	<b>19,393</b>	<b>20,947</b>	<b>23,128</b>
Exceptional Items	-1,000	0	-850	16	-5	0	0	0	0
<b>Reported PAT</b>	<b>14,454</b>	<b>17,160</b>	<b>17,483</b>	<b>17,184</b>	<b>18,427</b>	<b>17,676</b>	<b>19,124</b>	<b>20,617</b>	<b>22,798</b>

### Balance Sheet

(InR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Share Capital	1,767	1,767	1,768	1,772	1,772	1,772	1,774	1,774	1,774
Reserves	64,290	74,868	82,045	87,961	96,891	1,06,235	1,12,422	1,14,931	1,16,915
<b>Net Worth</b>	<b>66,057</b>	<b>76,635</b>	<b>83,813</b>	<b>89,733</b>	<b>98,663</b>	<b>1,08,007</b>	<b>1,14,195</b>	<b>1,16,704</b>	<b>1,18,689</b>
Minority Interest	365	367	406	4,682	4,368	4,096	3,832	4,203	4,618
Loans	4,718	4,847	10,072	11,434	11,581	7,301	10,627	10,427	10,227
<b>Capital Employed</b>	<b>71,140</b>	<b>81,849</b>	<b>94,291</b>	<b>1,05,848</b>	<b>1,14,612</b>	<b>1,19,404</b>	<b>1,28,654</b>	<b>1,31,334</b>	<b>1,33,534</b>
Gross Block	32,935	35,238	39,265	53,541	59,488	65,673	69,853	66,589	71,089
Less: Accum. Deprn.	-13,768	-16,169	-18,698	-21,807	-25,799	-30,255	-34,945	-40,082	-45,559
<b>Net Fixed Assets</b>	<b>19,167</b>	<b>19,069</b>	<b>20,568</b>	<b>31,734</b>	<b>33,689</b>	<b>35,417</b>	<b>34,908</b>	<b>26,507</b>	<b>25,529</b>
Capital WIP	1,466	1,473	1,675	1,751	2,091	1,690	1,388	1,388	1,388
Goodwill	3,360	3,360	2,512	4,053	4,051	4,051	4,051	3,551	3,051
<b>Investments</b>	<b>28,003</b>	<b>41,484</b>	<b>62,102</b>	<b>62,574</b>	<b>69,254</b>	<b>75,114</b>	<b>89,898</b>	<b>92,398</b>	<b>94,898</b>
<b>Curr. Assets, L&amp;A</b>	<b>41,325</b>	<b>42,199</b>	<b>35,983</b>	<b>37,854</b>	<b>42,079</b>	<b>46,026</b>	<b>44,502</b>	<b>47,969</b>	<b>51,962</b>
Inventory	13,796	17,343	19,114	20,242	19,470	23,001	23,216	22,921	24,271
Account Receivables	8,139	5,616	6,462	8,488	8,987	8,885	7,154	7,797	8,369
Cash and Bank Balance	8,114	12,710	5,387	4,703	6,664	5,780	5,621	8,062	9,395
Others	11,277	6,531	5,021	4,422	6,958	8,360	8,510	9,190	9,926
<b>Curr. Liab. and Prov.</b>	<b>22,226</b>	<b>26,484</b>	<b>27,732</b>	<b>31,229</b>	<b>35,525</b>	<b>41,476</b>	<b>44,583</b>	<b>38,969</b>	<b>41,784</b>
Current Liabilities	19,475	23,126	23,884	28,446	32,343	38,157	40,694	35,447	38,050
Provisions	2,751	3,357	3,847	2,784	3,182	3,320	3,889	3,523	3,734
<b>Net Current Assets</b>	<b>19,099</b>	<b>15,716</b>	<b>8,251</b>	<b>6,625</b>	<b>6,554</b>	<b>4,550</b>	<b>-81</b>	<b>9,000</b>	<b>10,177</b>
Deferred Tax Liability	46	747	-816	-889	-1,027	-1,417	-1,509	-1,509	-1,509
<b>Application of Funds</b>	<b>71,140</b>	<b>81,849</b>	<b>94,291</b>	<b>1,05,848</b>	<b>1,14,612</b>	<b>1,19,404</b>	<b>1,28,654</b>	<b>1,31,334</b>	<b>1,33,534</b>

E: MOFSL Estimates

## Financials and valuations

### Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
<b>Basic (INR)</b>									
EPS	8.7	9.7	10.4	9.7	10.6	10.2	10.9	11.8	13.0
Cash EPS	9.4	11.1	11.3	11.5	12.7	12.5	13.4	14.5	15.9
BV/Share	37.4	43.4	47.4	50.6	55.7	60.9	64.4	65.8	66.9
DPS	4.5	4.8	4.8	5.2	5.5	8.0	9.5	11.0	12.5
Payout %	51.5	48.9	45.8	53.7	52.0	78.7	86.9	93.1	95.9
<b>Valuation (x)</b>									
P/E	53.7	48.4	45.3	48.5	44.4	46.3	43.0	39.8	36.0
Cash P/E	49.9	42.5	41.5	41.0	37.1	37.6	35.0	32.4	29.5
EV/Sales	9.2	8.2	7.1	6.7	6.2	6.0	5.7	5.2	4.8
EV/EBITDA	44.6	38.6	34.2	35.8	32.0	32.8	30.5	27.4	24.7
P/BV	12.6	10.8	9.9	9.3	8.4	7.7	7.3	7.1	7.0
Dividend Yield (%)	1.0	1.0	1.0	1.1	1.2	1.7	2.0	2.3	2.7
<b>Return Ratios (%)</b>									
RoE	25.3	24.1	22.9	19.8	19.9	17.4	17.5	18.1	19.7
RoCE	23.9	22.8	21.2	17.7	17.3	15.9	16.1	16.3	17.6
RoIC	45.9	49.4	60.8	46.1	41.9	39.3	44.7	53.9	63.9
<b>Working Capital Ratios</b>									
Debtor (Days)	34	21	22	27	26	26	20	20	20
Asset Turnover (x)	1.2	1.2	1.2	1.1	1.1	1.1	1.0	1.1	1.2
<b>Leverage Ratio</b>									
Debt/Equity (x)	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1

### Cash Flow Statement

(INR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(loss) before Tax	17,276	20,787	22,778	22,187	23,587	22,579	24,204	27,000	29,848
Int./Div. Received	2,553	2	39	-1,038	-2,201	-566	-208	370	416
Depreciation & Amort.	2,205	2,401	2,529	3,110	3,992	4,456	4,689	5,137	5,477
Interest Paid	-2,001	308	386	-2,829	-2,689	-2,447	-2,208	1,300	1,200
Direct Taxes Paid	-3,089	-3,611	-5,264	-4,945	-4,939	-4,045	-3,988	-6,749	-7,461
(Incr)/Decr in WC	-580	7,979	141	-1,601	2,385	-110	3,297	-6,640	156
<b>CF from Oper.</b>	<b>16,364</b>	<b>27,867</b>	<b>20,609</b>	<b>14,884</b>	<b>20,135</b>	<b>19,868</b>	<b>25,786</b>	<b>20,419</b>	<b>29,636</b>
(Incr)/Decr in FA	-4,175	-2,311	-3,381	-4,857	-5,609	-5,695	-4,201	3,764	-4,000
<b>Free Cash Flow</b>	<b>12,190</b>	<b>25,556</b>	<b>17,228</b>	<b>10,027</b>	<b>14,526</b>	<b>14,172</b>	<b>21,585</b>	<b>24,183</b>	<b>25,636</b>
(Pur)/Sale of Invt.	-84,788	-13,481	-20,618	-4,950	-7,978	-61,884	-74,382	-2,500	-2,500
Others	86,031	-878	1,515	4,591	7,025	60,882	64,995	-5	-5
<b>CF from Invest.</b>	<b>-2,931</b>	<b>-16,670</b>	<b>-22,484</b>	<b>-5,216</b>	<b>-6,562</b>	<b>-6,698</b>	<b>-13,588</b>	<b>1,259</b>	<b>-6,505</b>
Issue of Shares	1	-501	-1,006	4	0	0	1	0	0
(Incr)/Decr in Debt	-1,751	129	5,226	488	-472	-2,168	-387	-200	-200
Dividend Paid	-6,178	-5,921	-9,281	-9,213	-9,658	-9,748	-14,190	-17,737	-20,398
Others	-673	-308	-386	-1,631	-1,483	-2,138	2,217	-1,300	-1,200
<b>CF from Fin. Act.</b>	<b>-8,601</b>	<b>-6,602</b>	<b>-5,448</b>	<b>-10,352</b>	<b>-11,612</b>	<b>-14,053</b>	<b>-12,357</b>	<b>-19,237</b>	<b>-21,798</b>
<b>Incr/Decr of Cash</b>	<b>4,832</b>	<b>4,596</b>	<b>-7,323</b>	<b>-684</b>	<b>1,961</b>	<b>-883</b>	<b>-159</b>	<b>2,441</b>	<b>1,333</b>
Add: Opening Bal.	3,282	8,114	12,710	5,387	4,703	6,664	5,780	5,621	8,062
<b>Closing Balance</b>	<b>8,114</b>	<b>12,710</b>	<b>5,387</b>	<b>4,703</b>	<b>6,664</b>	<b>5,780</b>	<b>5,621</b>	<b>8,062</b>	<b>9,395</b>

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

**Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://qalaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

**Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

**For Hong Kong:**

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

**For U.S.**

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

**For Singapore**

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani  
Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)  
Contact: (+65) 8328 0276

**Specific Disclosures**

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.